泰里巴拉提德作为肺移植接受者严重骨质疏松症的治疗方法
Lisa M Raven1,2,3, Louise Goodall1, Jacqueline R Center1,2,4
1Department of Diabetes and Endocrinology, St Vincent's Hospital Sydney, Sydney 2010, Australia.
JCEM case reports
|March 18, 2024
概括
甲基治疗药物特里巴拉提德 (Teriparatide) 有效地增加了严重骨质疏松症的肺移植患者的骨密度. 这项研究表明,对于这种患者群体来说,特里巴拉提德是一种安全有效的选择.
科学领域:
- 移植医学 移植医学 移植医学
- 内分泌学 在内分泌学.
- 骨的新陈代谢 骨的新陈代谢
背景情况:
- 骨质疏松症和骨质疏松症在接受肺移植 (LTx) 患者中非常普遍,超过其他固体器官移植人群的发病率.
- 即使使用抗吸收疗法,骨折率仍然很高,这凸显了LTx患者需要替代治疗的需要.
- 关于合成代谢剂在肺移植后的骨损失中有效性和安全性的数据有限.
研究的目的:
- 评估teriparatide在接受肺移植患者的严重骨质疏松症治疗中的安全性和有效性.
- 在这个特定的患者队列中,评估治疗后骨矿物质密度 (BMD) 的变化.
主要方法:
- 分析了3名肺移植接受者患有严重骨质疏松症的病例系列.
- 患者接受了18个月的特里巴提德 (每天20微克),以及维护前尼松和先前的佐勒德罗纳特治疗.
- 在治疗前和治疗后测量了骨矿物质密度;在一个病人身上监测了骨周转率.
主要成果:
- 所有3名患者都显示骨矿物质密度显著增加.
- 腰椎骨髓骨质量增加了12%的中位数 (范围,2%-14%).
- 骨近端骨总体BMD增加了8%的中位数 (范围,8%-10%),没有报告的不良影响.
结论:
- 特里巴拉提德似乎是肺移植患者严重骨质疏松症的安全有效的合成代谢治疗方法.
- 需要进一步的研究,以在更大的研究中证实这些发现.
- 这些发现表明,teriparatide是LTx患者骨损失的潜在治疗选择.
相关概念视频
01:27Pneumothorax-II
145
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
145
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
164
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
164
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
161
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
161
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
176
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
176